News & Insights

Stay informed with transaction announcements, firm news, and strategic insights from D. Boral Capital.

News & Insights

Published by D. Boral Capital

D. Boral Capital Secures Strategic Investments from Global Investment Bank ARC Group and an Institutional Investor

D. Boral Capital Secures Strategic Investments from Global Investment Bank ARC Group and an Institutional Investor

Read More →
D. Boral Capital Served as Co-Placement Agent to Kairos Pharma, Ltd. In connection with its $3.5 Million Private Placement

D. Boral Capital Served as Co-Placement Agent to Kairos Pharma, Ltd. In connection with its $3.5 Million Private Placement

Read More →
D. Boral Capital Served as the Sole Underwriter on the IPO of BurTech Acquisition Corp (Nasdaq: BRKH) which Recently Completed an ~$894 Million Business Combination with Blaize, Inc. (“Blaize”)

D. Boral Capital Served as the Sole Underwriter on the IPO of BurTech Acquisition Corp (Nasdaq: BRKH) which Recently Completed an ~$894 Million Business Combination with Blaize, Inc. (“Blaize”)

Read More →
D. Boral Capital Served as Placement Agent to Nature’s Miracle Holding, Inc. with its up to $29.7 Million Financing

D. Boral Capital Served as Placement Agent to Nature’s Miracle Holding, Inc. with its up to $29.7 Million Financing

Read More →
D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

Read More →
A New Wave in Neurodegeneration Treatment: How Clene’s CNS Gold Nano-Particle Program (CNM-Au8®) Aims to Target Disease Progression in ALS, MS, and PD.

A New Wave in Neurodegeneration Treatment: How Clene’s CNS Gold Nano-Particle Program (CNM-Au8®) Aims to Target Disease Progression in ALS, MS, and PD.

Read More →
Transforming Critical Care: CytoSorbents’ Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review

Transforming Critical Care: CytoSorbents’ Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review

Read More →
Beyond Air: Commercial Momentum and Global Expansion Driven by LungFit PH

Beyond Air: Commercial Momentum and Global Expansion Driven by LungFit PH

Read More →
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

Read More →
D. Boral Capital Acted as Exclusive Placement Agent to Webuy Global Ltd. (Nasdaq: WBUY) in connection with its $3.7 Million Registered Direct Offering

D. Boral Capital Acted as Exclusive Placement Agent to Webuy Global Ltd. (Nasdaq: WBUY) in connection with its $3.7 Million Registered Direct Offering

Read More →
D. Boral Capital Served as Exclusive Placement Agent to ConnectM Technology Solutions (Nasdaq: CNTM) in connection with its up to $25.0 Million Private Placement

D. Boral Capital Served as Exclusive Placement Agent to ConnectM Technology Solutions (Nasdaq: CNTM) in connection with its up to $25.0 Million Private Placement

Read More →
D. Boral Capital: Philanthropic Endeavors Continue with Donations to Keep a Child Alive and Project Rosseau

D. Boral Capital: Philanthropic Endeavors Continue with Donations to Keep a Child Alive and Project Rosseau

Read More →